Comment on: 'Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know?'.
- Published in:
- 2023
- By:
- Publication type:
- Letter to the Editor
Works matching IS 00126667 AND DT 2023 AND VI 83 AND IP 7
Results: 8
1
2
Authors' Reply to Chia Siang Kow et al.: Comment on: 'Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far?'.
- Published in:
- 2023
- By:
- Publication type:
- Letter
3
Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study.
- Published in:
- Drugs, 2023, v. 83, n. 7, p. 621, doi. 10.1007/s40265-023-01867-8
- By:
- Publication type:
- Article
4
Efanesoctocog Alfa: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 7, p. 633, doi. 10.1007/s40265-023-01866-9
- By:
- Publication type:
- Article
5
Keverprazan Hydrochloride: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 7, p. 639, doi. 10.1007/s40265-023-01865-w
- By:
- Publication type:
- Article
6
The Comparative Effectiveness and Safety of Insomnia Drugs: A Systematic Review and Network Meta-Analysis of 153 Randomized Trials.
- Published in:
- Drugs, 2023, v. 83, n. 7, p. 587, doi. 10.1007/s40265-023-01859-8
- By:
- Publication type:
- Article
7
Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?
- Published in:
- Drugs, 2023, v. 83, n. 7, p. 577, doi. 10.1007/s40265-023-01862-z
- By:
- Publication type:
- Article
8
Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics.
- Published in:
- Drugs, 2023, v. 83, n. 7, p. 569, doi. 10.1007/s40265-023-01858-9
- By:
- Publication type:
- Article